Nektar Therapeutics Q2 FY25: revenue $11.2M, down 52%; diluted EPS −$42.14

Key figures from this report

These are the numbers Nektar Therapeutics reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$11.2M−52% from $23.5M in Q2 FY2410-Q income statement, on EDGAR
2. Net income−$41.6MAgainst −$52.4M in Q2 FY2410-Q income statement, on EDGAR
3. Diluted EPS−$42.14Against −$765.30 in Q2 FY24. Split-adjusted, as the tables show it; the filing reported −$2.9510-Q income statement, on EDGAR
4. Cash and cash equivalents$43.0M+54% from $27.9M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$45.7MAgainst −$37.7M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables